STRASBOURG, France, Feb. 15 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Euronext: FR0005175080) announced today the appointment of Dr. Jean-Yves Bonnefoy as its new Chief Scientific Officer. He replaces Serge Braun who has decided to pursue other opportunities outside of the Company.

Prior to joining Transgene, Jean-Yves Bonnefoy, 45, was Head of the Canceropole Lyon Rhones-Alpes. From 1997 to 2002, he was Director of the Immunology Center of the Pierre Fabre Group in Saint-Julien en Genevois, France. He previously was responsible for the Immunology Department of the Biomedical Research Institute of the Glaxo-Wellcome Group in Geneva, Switzerland. Jean-Yves Bonnefoy holds a PhD in immunology from the Lyons Claude Bernard University and has completed the Senior Management Program of the London Business School.

"We thank Serge Braun for his contribution to the development of Transgene," stated Philippe Archinard, Chief Executive Officer of Transgene. "We are delighted to integrate Jean-Yves' immunology experience and background in the infectiology and oncology fields. His arrival will allow us to reinforce Transgene as a company dedicated to therapeutic vaccination."

This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.

For full details, please email keithw@cmsinfo.com